glp-1 incretin effect Photography Poster Incretin Effect GLP-1

Both GIP receptor agonism and antagonism were able to reduce body weight or prevent diet-induced obesity in mice [18]

L., Rennert, H

From its initial use in the treatment of type 2 diabetes to its expansion to 12 indications such as obesity, cardiovascular disease, chronic kidney disease, and metabolic dysfunction related fatty liver disease (MASLD), the annual sales of GLP-1 drugs exceeded 100 billion dollars, and its research and development funding reached a historical peak of 21.72 million dollars in 2025

Mounjaro (tirzepatide): EPAR product information

For slots fans, verify volatility, feature frequency, and maximum exposure so you can calibrate sessions to your budget and temperament without surprises